Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2016 - 2022)

Sonoma Pharmaceuticals (SNOA) has 3 years of Cash & Equivalents data on record, last reported at $6.6 million in Q4 2012.

  • For Q4 2012, Cash & Equivalents rose 33.0% year-over-year to $6.6 million; the TTM value through Dec 2012 reached $6.6 million, up 33.0%, while the annual FY2012 figure was $3.4 million, 23.34% down from the prior year.
  • Cash & Equivalents reached $6.6 million in Q4 2012 per SNOA's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $8.3 million in Q3 2012 and bottomed at $3.4 million in Q1 2012.
  • Average Cash & Equivalents over 3 years is $5.2 million, with a median of $5.0 million recorded in 2011.
  • Peak YoY movement for Cash & Equivalents: tumbled 32.51% in 2011, then skyrocketed 129.43% in 2012.
  • A 3-year view of Cash & Equivalents shows it stood at $4.7 million in 2010, then rose by 6.16% to $5.0 million in 2011, then skyrocketed by 33.0% to $6.6 million in 2012.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $6.6 million in Q4 2012, $8.3 million in Q3 2012, and $4.4 million in Q2 2012.